Comparison · NCT01778634-a5cc0673
Azithromycin vs Placebo (5% Dextrose): Number of Participants With Periventricular Leukomalacia (PVL)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Azithromycin vs Placebo (5% Dextrose): Number of Participants With Periventricular Leukomalacia (PVL). Trial comparisons, record NCT01778634-a5cc0673. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01778634-a5cc0673
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0667 | 0.0262 | 0.159 | wilson | |
| Risk in group 2 | 0.082 | 0.0355 | 0.178 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0153 | -0.119 | 0.0883 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.813 | 0.229 | 2.88 | log | |
| Odds ratio, group 1 over group 2 | 0.8 | 0.204 | 3.14 | log | |
| Number needed to treat, for one fewer participant with the outcome on Azithromycin than on Placebo (5% Dextrose) | 65.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Azithromycin | Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days~Azithromycin: Azithromycin intravenous 20 mg/kg every 24 h x 3 days | 4 | 60 | OG001 |
| Group 2 | Placebo (5% Dextrose) | Placebo~Placebo: D5W 10 ml/kg every 24 h x 3 days | 5 | 61 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- OTHER_PRE_SPECIFIED
- Title
- Number of Participants With Periventricular Leukomalacia (PVL)
- Description
- The number of Participants with cranial ultrasound confirmed PVL
- Time frame
- Participants will be followed for the duration of hospital stay, an expected average of 10 weeks
- Population
Source ClinicalTrials.gov
Trial
- Title
- Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants
- NCT number
- NCT01778634
- Phases
- PHASE2
- Conditions
- Ureaplasma Infections
- Interventions
- Azithromycin, Placebo
- Lead sponsor
- University of Maryland, Baltimore
- Results first posted
- 2018-05-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01778634?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01778634-a5cc0673